- Conditions
- Post-Surgical Hypoparathyroidism
- Interventions
- encaleret
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Interventions
- Encaleret
- Drug
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Jacksonville, Florida + 1 more
- Conditions
- Autosomal Dominant Hypocalcemia (ADH)
- Interventions
- Encaleret, Standard of Care
- Drug · Dietary Supplement
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 11
- States / cities
- Oakland, California • Aurora, Colorado • Indianapolis, Indiana + 8 more
- Conditions
- Hypoparathyroidism, Chronic Hypoparathyroidism
- Interventions
- Encaleret, Placebo
- Drug
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 4
- States / cities
- Reno, Nevada • Greenville, North Carolina • Morehead City, North Carolina + 1 more
- Conditions
- Autosomal Dominant Hypocalcemia
- Interventions
- Not listed
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- Up to 90 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 9
- States / cities
- Oakland, California • Aurora, Colorado • Jacksonville, Florida + 6 more
- Conditions
- Autosomal Dominant Hypocalcemia (ADH), Autosomal Dominant Hypocalcemia Type 1 (ADH1)
- Interventions
- Encaleret
- Drug
- Lead sponsor
- Calcilytix Therapeutics, Inc., a BridgeBio company
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland